Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients
Lauren N. Krumeich, Jenna Mancinelli, Andy Cucchiara, Kevin Eddinger, David Aufhauser, Drew W. Goldberg, Evan S. Siegelman, Mark Rosen, K. Rajender Reddy, Maarouf Hoteit, Emma E. Furth, Kim M. Olthoff, Abraham Shaked, Matthew Levine, Peter Abt – 13 April 2021 – Transplant eligibility for hepatocellular carcinoma (HCC) is determined by the imaging identification of tumor burden within the Milan criteria. Transjugular intrahepatic portosystemic shunt(s) (TIPS) reduce portal hypertension but may impact HCC visualization.